Intellia Therapeutics to Present at March Investor Healthcare Conferences

CAMBRIDGE, Mass., March 01, 2017 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that company senior leaders will present at key March investor healthcare conferences, including the Cowen and Company 37^th Annual Health Care Conference, the Goldman Sachs Third Annual Innovation Symposium, and the Oppenheimer 27^th Annual Healthcare Conference.

Details of the upcoming presentations are as follows:

Wednesday, March 8^th
Cowen and Company 37^th Annual Health Care Conference
Who: Nessan Bermingham, Ph.D., chief executive officer & founder
Location: Boston, Massachusetts
Presentation Time: 8:40 am ET

Wednesday, March 15^th
The Goldman Sachs Third Annual Innovation Symposium
Gene Editing and CRISPR Panel
Who: Nessan Bermingham, Ph.D., chief executive officer & founder
Location: New York, New York
Panel Time: 10:15 am ET

Wednesday, March 22^nd
The Oppenheimer 27^th Annual Healthcare Conference
Who: John Leonard, M.D., executive vice president, R&D
Location: New York, New York
Presentation Time: 2:45 pm ET

Individuals may access the presentations for available conferences via live webcast on the Intellia website at www.intelliatx.com under "Events & Presentations" in the "Investor Relations" section. When available, replays of these webcasts will be available on the site for 90 days following the live events.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.

Media Contact:
Jennifer Mound Smoter 
Senior Vice President, External Affairs & Communications
+1 (857) 706-1071
[email protected]

Investor Contact:
Graeme Bell
Chief Financial Officer
+1 (857) 706-1081 
[email protected]